Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis.

Kuroda T, Tanabe N, Kobayashi D, Sato H, Wada Y, Murakami S, Saeki T, Nakano M, Narita I.

J Rheumatol. 2012 Jul;39(7):1348-54. doi: 10.3899/jrheum.111453. Epub 2012 May 15.

PMID:
22589255
2.

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.

Kuroda T, Tanabe N, Nozawa Y, Sato H, Nakatsue T, Kobayashi D, Wada Y, Saeki T, Nakano M, Narita I.

Intern Med. 2016;55(19):2777-2783. Epub 2016 Oct 1.

3.
4.

Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis.

Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, Tanabe N, Saeki T, Nakano M, Narita I.

J Rheumatol. 2009 Nov;36(11):2409-15. doi: 10.3899/jrheum.090101. Epub 2009 Oct 1.

PMID:
19797512
5.

[Secondary amyloidosis in rheumatoid arthritis. A clinical study of 29 patients].

Fiter Aresté J, Nolla Solé JM, Gómez Vaquero C, Valverde García J, Roig Escofet D.

An Med Interna. 1999 Dec;16(12):615-9. Spanish.

PMID:
10686712
6.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
7.

Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M.

Rheumatology (Oxford). 2012 Nov;51(11):2064-9. doi: 10.1093/rheumatology/kes190. Epub 2012 Aug 9.

PMID:
22879465
8.
9.

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X.

Arthritis Rheum. 2003 Jul;48(7):2019-24.

10.

Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis.

Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M.

Rheumatology (Oxford). 2006 Jan;45(1):43-9. Epub 2005 Oct 11.

PMID:
16219644
11.

Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.

Smith GR, Tymms KE, Falk M.

Intern Med J. 2004 Sep-Oct;34(9-10):570-2.

PMID:
15482271
12.

When first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence.

Burkart J, Benson DM Jr.

Joint Bone Spine. 2013 Mar;80(2):229-30. doi: 10.1016/j.jbspin.2012.08.008. Epub 2012 Sep 28. No abstract available.

PMID:
23022420
13.

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R.

Am J Med. 2005 May;118(5):552-6. No abstract available. Erratum in: Am J Med. 2006 Feb;119(2):191. Garcia-Vicuna, Rosa [corrected to Portales, Rosa García ].

PMID:
15866260
14.

A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.

Pamuk ÖN, Kalyoncu U, Aksu K, Omma A, Pehlivan Y, Çağatay Y, Küçükşahin O, Dönmez S, Çetin GY, Mercan R, Bayındır Ö, Çefle A, Yıldız F, Balkarlı A, Kılıç L, Çakır N, Kısacık B, Öksüz MF, Çobankara V, Onat AM, Sayarlıoğlu M, Öztürk MA, Pamuk GE, Akkoç N.

Rheumatol Int. 2016 Jul;36(7):945-53. doi: 10.1007/s00296-016-3500-9. Epub 2016 May 24.

PMID:
27221456
15.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
16.

The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.

Bingham SJ, Buch MH, Tennant A, Emery P.

Rheumatology (Oxford). 2004 Mar;43(3):364-8. Epub 2003 Dec 1.

PMID:
14657509
17.
18.

Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Nakamura T, Kumon Y, Hirata S, Takaoka H.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):501-8. Epub 2014 Jun 23.

PMID:
24959698
19.
20.

Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.

Sullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, Ringold S.

J Med Econ. 2013;16(3):391-6. doi: 10.3111/13696998.2013.763812. Epub 2013 Jan 18. Review.

PMID:
23298329

Supplemental Content

Support Center